In the mid-stage trial, 109 patients were injected with NeuVax and an immune system booster, while 79 women were untreated.
According the data, 6.5 percent of the women treated with NeuVax had a breast cancer relapse after 24 months compared to 14.5 percent of the women in the control group.
At 36 months the cancer relapse rate for NeuVax-treated women was 8.5 percent compared to 14.5 percent relapse rate for the control group.
So for the time period between 24 months and 36 months the patients on the placebo did better (8.5% up from 6.5%) whereas the patients on neuvax remained at 14.6%.
The results was statistically insignificant and were trending in the wrong direction.
It suggests that the results for 60 months will narrow even more.
Even if they remain at the 36 month level, it would no be sufficient for approval.
The trial is doomed.
It explains why the insiders bailed.
What you fail to understand is that Apthera ran a P2 trial. It failed. They then data mined and claimed that Neuvax works for a subset of women, those in remission after front line treatment. That an injection of Neuvax would prevent the recurrence of cancer. That subset was 100% disease free after the frontline treatment. It's tom foolery.
Don't fall for it. ======= the insiders bailed ======= you should too.
The scammers are trying to get saps to buy at $1.41.
That will FAIL in 2018 - 2019.